Telegraph Hill Partners — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Director)Paulo Garcia(Executive Officer, Director, Promoter)Michael Chiu(Director, Executive Officer)
BoardPaxton Major(Director)Ann DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsThe Engine Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.